Topic

Blenrep (belantamab mafodotin)

A collection of 15 issues

How to Get Blenrep (belantamab mafodotin) Covered by Aetna in Illinois: Complete Timeline & Appeals Guide

Answer Box: Getting Blenrep Covered by Aetna in Illinois Blenrep (belantamab mafodotin) received FDA approval on October 23, 2025 for relapsed/refractory multiple myeloma. For Aetna coverage in Illinois: 1. Check eligibility: Must have relapsed/refractory multiple myeloma after ≥2 prior therapies including a proteasome inhibitor and immunomodulatory agent 2.

How to Get Blenrep (Belantamab Mafodotin) Covered by Blue Cross Blue Shield of Illinois: Coding, Appeals, and Current Access Options

Answer Box: Blenrep Coverage with Blue Cross Blue Shield of Illinois Current Status: Blenrep (belantamab mafodotin) is not commercially available in the U.S. as of 2025—GSK withdrew it in 2022 pending FDA resubmission (PDUFA date October 2025). Blue Cross Blue Shield of Illinois (BCBSIL) requires prior authorization for

How to Get Blenrep (belantamab mafodotin) Covered by Aetna in New York: Complete Guide to Appeals and Access

Quick Answer: Getting Blenrep Covered by Aetna in New York Important Update: Blenrep (belantamab mafodotin) was voluntarily withdrawn from the U.S. market in 2022 and is currently under FDA review with a decision expected October 23, 2025. Standard commercial coverage through Aetna is not available at this time. Current

How to Get Blenrep (belantamab mafodotin) Covered by Aetna in California: Decision Tree, Appeals, and Access Options

Answer Box: Your Path to Blenrep Coverage in California Blenrep (belantamab mafodotin) is currently unavailable for commercial coverage through Aetna CVS Health because GSK withdrew it from the U.S. market in November 2022. The FDA is reviewing resubmission with a PDUFA date of October 23, 2025. Your fastest path

Getting Blenrep (Belantamab Mafodotin) Covered by Humana in Virginia: Complete Guide to Access, Appeals, and Clinical Trial Options

Answer Box: Quick Path to Blenrep Access in Virginia Blenrep (belantamab mafodotin) is currently unavailable for commercial coverage in the U.S. as GSK resubmits for FDA approval (decision expected October 23, 2025). Virginia patients with Humana can access Blenrep only through: 1. Clinical trials - Contact your oncologist about